Castle Biosciences, Inc. CSTL
$34.97
$1.534.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 23.74% | -3.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.74% | -3.83% | |||
| Cost of Revenue | 15.42% | 12.11% | |||
| Gross Profit | 26.45% | -8.08% | |||
| SG&A Expenses | 1.88% | 14.40% | |||
| Depreciation & Amortization | 1.12% | -2.20% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.44% | 12.38% | |||
| Operating Income | 83.32% | -380.98% | |||
| Income Before Tax | 88.27% | -431.06% | |||
| Income Tax Expenses | 239.45% | 128.53% | |||
| Earnings from Continuing Operations | 85.81% | -522.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 85.81% | -522.73% | |||
| EBIT | 83.32% | -380.98% | |||
| EBITDA | 106.91% | -28,856.00% | |||
| EPS Basic | 86.05% | -511.19% | |||
| Normalized Basic EPS | 93.66% | -1,778.14% | |||
| EPS Diluted | 85.59% | -511.19% | |||
| Normalized Diluted EPS | 93.66% | -1,778.14% | |||
| Average Basic Shares Outstanding | 1.71% | 1.90% | |||
| Average Diluted Shares Outstanding | 1.71% | 1.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||